ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies

Author(s): Nooshafarin Amani*, Farid Abedin Dorkoosh, Hamid Mobedi.

Journal Name: Current Drug Delivery

Volume 17 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Antibody drug conjugates (ADCs), as potent pharmaceutical trojan horses for cancer treatment, provide superior efficacy and specific targeting along with low risk of adverse reactions compared to traditional chemotherapeutics. In fact, the development of these agents combines the selective targeting capability of monoclonal antibody (mAb) with high cytotoxicity of chemotherapeutics for controlling the neoplastic mass growth. Different ADCs (more than 60 ADCs) in preclinical and clinical trials were introduced in this novel pharmaceutical field. Various design-based factors must be taken into account for improving the functionality of ADC technology, including selection of appropriate target antigen and high binding affinity of fragment (miniaturized ADCs) or full mAbs (preferentially use of humanized or fully human antibodies compared to murine and chimeric ones), use of bispecific antibodies for dual targeting effect, linker engineering and conjugation method efficacy to obtain more controlled drug to antibody ratio (DAR). Challenging issues affecting therapeutic efficacy and safety of ADCs, including bystander effect, on- and off-target toxicities, multi drug resistance (MDR) are also addressed. 4 FDA-approved ADCs in the market, including ADCETRIS ®, MYLOTARG®, BESPONSA ®, KADCYLA®. The goal of the current review is to evaluate the key parameters affecting ADCs development.

Keywords: Immuno conjugate, selective targeting strategy, site-specific conjugation, antibody, drug delivery, hematological and solid tumor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [23 - 51]
Pages: 29
DOI: 10.2174/1567201816666191121145109

Article Metrics

PDF: 6